These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29548573)

  • 1. Identification of second-generation P2X3 antagonists for treatment of pain.
    Ginnetti AT; Paone DV; Stauffer SR; Potteiger CM; Shaw AW; Deng J; Mulhearn JJ; Nguyen DN; Segerdell C; Anquandah J; Calamari A; Cheng G; Leitl MD; Liang A; Moore E; Panigel J; Urban M; Wang J; Fillgrove K; Tang C; Cook S; Kane S; Salvatore CA; Graham SL; Burgey CS
    Bioorg Med Chem Lett; 2018 May; 28(8):1392-1396. PubMed ID: 29548573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent Antiallodynic Agents for Neuropathic Pain Targeting P2X3 Receptors.
    Jung YH; Kim YO; Lin H; Cho JH; Park JH; Lee SD; Bae J; Kang KM; Kim YG; Pae AN; Ko H; Park CS; Yoon MH; Kim YC
    ACS Chem Neurosci; 2017 Jul; 8(7):1465-1478. PubMed ID: 28323403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.
    Kai H; Horiguchi T; Kameyma T; Onodera N; Itoh N; Fujii Y; Ichihashi Y; Hirai K; Shintani T; Nakamura K; Minami K; Kasai E; Yoneda S; Murakami Y; Ogawa H; Sekimoto R; Shinohara S; Yoshida O; Kurose N
    Bioorg Med Chem Lett; 2021 Nov; 52():128384. PubMed ID: 34587541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.
    Tobinaga H; Kameyama T; Oohara M; Kobayashi N; Ohdan M; Ishizuka N; Kume M; Tomari M; Tanaka Y; Takahashi F; Kinoshita H; Shimada S; Shinohara S; Kai H
    Bioorg Med Chem Lett; 2018 Jul; 28(13):2338-2342. PubMed ID: 29805055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
    Szántó G; Makó A; Bata I; Farkas B; Kolok S; Vastag M; Cselenyák A
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3896-904. PubMed ID: 27423478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones.
    Szántó G; Makó A; Vágó I; Hergert T; Bata I; Farkas B; Kolok S; Vastag M
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3905-12. PubMed ID: 27426300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dioxotriazine derivatives as a new class of P2X
    Kai H; Horiguchi T; Kameyama T; Asahi K; Endoh T; Jikihara S; Hasegawa T; Tanaka S; Nozu A; Takeyama C; Tomari M; Takahashi F; Tamura N; Yagi S; Itoh T; Isou Y
    Bioorg Med Chem Lett; 2021 Apr; 37():127833. PubMed ID: 33540044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.
    Tobinaga H; Kameyama T; Asahi K; Horiguchi T; Oohara M; Taoda Y; Hata K; Hasegawa T; Tada Y; Kurihara N; Kanda Y; Yagi S; Tomari M; Tanaka Y; Takahashi F; Taniguchi E; Takahara Y; Shimada S; Takeyama C; Yamamoto S; Shinohara S; Kai H
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127636. PubMed ID: 33132115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.
    Tobinaga H; Kameyama T; Asahi K; Horiguchi T; Oohara M; Tada Y; Fuchino K; Jikihara S; Endoh T; Kurihara N; Kanda Y; Ogawa M; Tamura N; Yagi S; Taniguchi E; Takahara Y; Shimada S; Takeyama C; Yamamoto S; Shinohara S; Kai H
    Bioorg Med Chem Lett; 2019 Mar; 29(5):688-693. PubMed ID: 30728111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
    Marucci G; Dal Ben D; Buccioni M; Martí Navia A; Spinaci A; Volpini R; Lambertucci C
    Expert Opin Ther Pat; 2019 Dec; 29(12):943-963. PubMed ID: 31726893
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.
    Subramanyam C; Duplantier AJ; Dombroski MA; Chang SP; Gabel CA; Whitney-Pickett C; Perregaux DG; Labasi JM; Yoon K; Shepard RM; Fisher M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5475-9. PubMed ID: 21782426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.
    Chrovian CC; Soyode-Johnson A; Peterson AA; Gelin CF; Deng X; Dvorak CA; Carruthers NI; Lord B; Fraser I; Aluisio L; Coe KJ; Scott B; Koudriakova T; Schoetens F; Sepassi K; Gallacher DJ; Bhattacharya A; Letavic MA
    J Med Chem; 2018 Jan; 61(1):207-223. PubMed ID: 29211470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Structure-Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents.
    Bae J; Kim YO; Han X; Yoon MH; Kim WM; Kim YC
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.
    Jung KY; Cho JH; Lee JS; Kim HJ; Kim YC
    Bioorg Med Chem; 2013 May; 21(9):2643-50. PubMed ID: 23510563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of P2X3 selective antagonists for the treatment of chronic pain.
    Cantin LD; Bayrakdarian M; Buon C; Grazzini E; Hu YJ; Labrecque J; Leung C; Luo X; Martino G; Paré M; Payza K; Popovic N; Projean D; Santhakumar V; Walpole C; Yu XH; Tomaszewski MJ
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2565-71. PubMed ID: 22370269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [P2x3-receptor desensitization as an alternative mechanism of analgesia].
    Petrenko NS; Kryshtal' OO
    Fiziol Zh (1994); 2013; 59(2):104-10. PubMed ID: 23828978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 2.
    Brumfield S; Matasi JJ; Tulshian D; Czarniecki M; Greenlee W; Garlisi C; Qiu H; Devito K; Chen SC; Sun Y; Bertorelli R; Ansell J; Geiss W; Le VD; Martin GS; Vellekoop SA; Haber J; Allard ML
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7287-90. PubMed ID: 22078214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrid-2-yl and 2-CyanoPhenyl fused heterocyclic compounds as human P2X3 inhibitors: a combined approach based on homology modelling, docking and QSAR analysis.
    Janardhan S; Seth S; Viswanadhan VN
    Mol Divers; 2014 Feb; 18(1):161-81. PubMed ID: 24154731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of P2X3 receptor structure and function.
    Fabbretti E; Nistri A
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):687-98. PubMed ID: 22963434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X
    Wilkinson SM; Barron ML; O'Brien-Brown J; Janssen B; Stokes L; Werry EL; Chishty M; Skarratt KK; Ong JA; Hibbs DE; Vugts DJ; Fuller S; Windhorst AD; Kassiou M
    ACS Chem Neurosci; 2017 Nov; 8(11):2374-2380. PubMed ID: 28841278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.